# Nilotinib in Cognitively Impaired Parkinson Disease Patients 001

> **NCT02281474** · PHASE1 · COMPLETED · sponsor: **Georgetown University** · enrollment: 12 (actual)

## Conditions studied

- Parkinson's Disease
- Parkinson's Disease Dementia
- Diffuse Lewy Body Disease

## Interventions

- **DRUG:** Nilotinib

## Key facts

- **NCT ID:** NCT02281474
- **Lead sponsor:** Georgetown University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2015-05
- **Final completion:** —
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2015-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02281474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02281474, "Nilotinib in Cognitively Impaired Parkinson Disease Patients 001". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02281474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*